ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "FK506"

  • 2021 American Transplant Congress

    Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction

    R. Winstead1, D. Kumar1, A. Brown1, I. Yakubu1, C. Song1, L. Thacker2, G. Gupta1

    1Virginia Commonwealth University Health, Richmond, VA, 2Virginia Commonwealth University, Richmond, VA

    *Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…
  • 2021 American Transplant Congress

    The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients

    D. Xu1, K. Richards1, K. Zheng1, H. Patel2, F. Cardarelli2, J. A. Pena3, A. Aala2

    1Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, 2Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, 3Pathology, Beth Israel Deaconess Medical Center, Boston, MA

    *Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…
  • 2021 American Transplant Congress

    Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients

    A. Demirag1, P. L. Lobo2, J. Oberholzer1, A. Kumar2, B. Rawashdeh1, S. L. Lennon1, H. N. Guvener Demirag1, A. Doyle2, J. Geystone3, K. L. Brayman1

    1Transplantation, University of Virginia Medical Center, Charlottesville, VA, 2Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, 3Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA

    *Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
  • 2021 American Transplant Congress

    De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience

    N. Singh1, T. Le1, M. S. Naseer1, S. Asmil1, A. Palermini1, A. Qamar1, R. Chand1, S. Tandukar1, D. Aultman2, H. Shokouh-Amiri2, G. Zibari2

    1Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, 2Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA

    *Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
  • 2021 American Transplant Congress

    The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients

    T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber

    Medical University of South Carolina, Charleston, SC

    *Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
  • 2021 American Transplant Congress

    The Learning Curve Associated with De Novo Tacrolimus XR Use in a Racially Diverse Kidney Transplant Population

    F. Bartlett, T. Carcella, N. Patel, V. Rohan, D. Taber

    Medical University of South Carolina, Charleston, SC

    *Purpose: Tacrolimus XR (LCP-Tac) was approved for de novo dosing in kidney transplant recipients in 2018. In 2020, our center was challenged with a nationwide…
  • 2021 American Transplant Congress

    Ectopic Hepatocyte Transplantation Into the Lymph Nodes in a Fully Mismatched Allogeneic Dog Model Using Tacrolimus and Prednisone

    P. A. Fontes

    NA, LyGenesis, Pittsburgh, PA

    *Purpose: Develop organogenesis through ectopic hepatocyte transplantation (HT) into the upper abdominal lymph nodes (LN).*Methods: Three groups of Mongrel dogs weighting between 25-35 kg (control…
  • 2020 American Transplant Congress

    Trust and Transparency in Artificial Intelligence-Aided Immunosuppression Decisions

    J. Clement

    Information and Decision Sciences, University of Minnesota, Minneapolis, MN

    *Purpose: In transplant, there is significant interest in using Artificial Intelligence (including machine learning or predictive models) Clinical Decision Support Systems(AI CDSS). Properly designing and…
  • 2020 American Transplant Congress

    Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients

    D. Nnani1, A. Campbell1, M. Ajaimy2, S. R. Patel3, O. Saeed3, D. J. Goldstein4, J. Graham5, U. P. Jorde3

    1Pharmacy, Montefiore Medical Center, Bronx, NY, 2Medicine, Montefiore Medical Center, Bronx, NY, 3Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, 4Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, 5Surgery, Montefiore Medical Center, Bronx, NY

    *Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…
  • 2020 American Transplant Congress

    Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model

    J. Banbury1, A. Dodson1, C. Lin2, K. Gutierrez1

    1University of Alabama at Birmingham Hospital, Birmingham, AL, 2Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL

    *Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences